Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

Joseph Fraiman, Juan Erviti, Mark Jones, Sander Greenland, Patrick Whelan, Robert M Kaplan, Peter Doshi, Joseph Fraiman, Juan Erviti, Mark Jones, Sander Greenland, Patrick Whelan, Robert M Kaplan, Peter Doshi

Abstract

Introduction: In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We adapted the Brighton Collaboration list to evaluate serious adverse events of special interest observed in mRNA COVID-19 vaccine trials.

Methods: Secondary analysis of serious adverse events reported in the placebo-controlled, phase III randomized clinical trials of Pfizer and Moderna mRNA COVID-19 vaccines in adults (NCT04368728 and NCT04470427), focusing analysis on Brighton Collaboration adverse events of special interest.

Results: Pfizer and Moderna mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events of special interest of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95 % CI -0.4 to 20.6 and -3.6 to 33.8), respectively. Combined, the mRNA vaccines were associated with an excess risk of serious adverse events of special interest of 12.5 per 10,000 vaccinated (95 % CI 2.1 to 22.9); risk ratio 1.43 (95 % CI 1.07 to 1.92). The Pfizer trial exhibited a 36 % higher risk of serious adverse events in the vaccine group; risk difference 18.0 per 10,000 vaccinated (95 % CI 1.2 to 34.9); risk ratio 1.36 (95 % CI 1.02 to 1.83). The Moderna trial exhibited a 6 % higher risk of serious adverse events in the vaccine group: risk difference 7.1 per 10,000 (95 % CI -23.2 to 37.4); risk ratio 1.06 (95 % CI 0.84 to 1.33). Combined, there was a 16 % higher risk of serious adverse events in mRNA vaccine recipients: risk difference 13.2 (95 % CI -3.2 to 29.6); risk ratio 1.16 (95 % CI 0.97 to 1.39).

Discussion: The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses, particularly those that are stratified according to risk of serious COVID-19 outcomes. These analyses will require public release of participant level datasets.

Keywords: Adverse events of special interest; Brighton Collaboration; COVID-19; COVID-19 vaccines; Coalition for Epidemic Preparedness Innovations; Moderna COVID-19 vaccine mRNA-1273; NCT04368728; NCT04470427; Pfizer-BioNTech COVID-19 vaccine BNT162b2; SARS-CoV-2; Safety Platform for Emergency vACcines; Serious adverse events; Vaccines; mRNA vaccines.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Copyright © 2022 Elsevier Ltd. All rights reserved.

References

    1. Law B, Pim C. SO2-D2.1.3 Priority List of COVID-19 Adverse events of special interest [Internet]. 2021 Oct [cited 2022 Feb 17]. Available from: .
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615.
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–416.
    1. Sadoff J., Gray G., Vandebosch A.n., Cárdenas V., Shukarev G., Grinsztejn B., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201.
    1. Health Canada. Search for clinical information on drugs and medical devices [Internet]. 2019 [cited 2021 Nov 9]. Available from: .
    1. Food and Drug Administration. Meeting Materials, Vaccines and Related Biological Products Advisory Committee [Internet]. U.S. Food and Drug Administration. 2022 [cited 2022 Feb 18]. Available from: .
    1. Law B. SO2-D2.1.2 Priority List of COVID-19 Adverse events of special interest: Quarterly update December 2020 [Internet]. 2020 Dec [cited 2020 Dec 20]. Available from: .
    1. Pfizer. PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001 [Internet]. 2020 [cited 2022 Jul 17]. Available from: .
    1. Pfizer-BioNTech. PFIZER-BIONTECH COVID-19 VACCINE (BNT162, PF-07302048) VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE BRIEFING DOCUMENT. [cited 2021 Dec 20]; Available from: .
    1. Pfizer. Final Analysis Interim Report: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (Protocol C4591001) [Internet]. [cited 2022 May 3]. Available from: .
    1. Moderna. Sponsor briefing document [Internet]. 2020 Dec [cited 2022 Feb 21]. Available from: .
    1. Moderna. Unblinded Safety Tables Batch 1 (DS2) [Internet]. [cited 2022 May 3]. Available from: .
    1. Amrhein V., Greenland S., McShane B. Scientists rise up against statistical significance. Nature. 2019;567(7748):305–307. doi: 10.1038/d41586-019-00857-9.
    1. Rafi Z, Greenland S. Semantic and cognitive tools to aid statistical science: replace confidence and significance by compatibility and surprise. BMC Med Res Methodol [Internet]. 2020 Sep 30;20(1):244. Available from: .
    1. Food and Drug Administration. Emergency Use Authorization for Pfizer-BioNTech COVID-19 Vaccine Review Memo [Internet]. 2020 Dec [cited 2022 Feb 21]. Available from: .
    1. Food and Drug Administration. Moderna COVID-19 Vaccine EUA FDA review memorandum [Internet]. 2020 Dec [cited 2022 Feb 21]. Available from: .
    1. Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine EUA review memorandum [Internet]. 2020 Dec [cited 2022 Mar 30]. Available from: .
    1. Food and Drug Administration. Initial Results of Near Real-Time Safety Monitoring COVID-19 Vaccines [Internet]. 2021 [cited 2022 Mar 30]. Available from: .
    1. Centers for Disease Control and Prevention. Selected adverse events reported after COVID-19 vaccination [Internet]. 2021 [cited 2021 May 28]. Available from: .
    1. Krug A, Stevenson J, Høeg TB. BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis. Eur J Clin Invest [Internet]. 2022 May;52(5):e13759. Available from: .
    1. Dutta S., Kaur R., Charan J., Bhardwaj P., Ambwani S.R., Babu S., et al. Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines. Cureus. 2022;14(1):e21376. doi: 10.7759/cureus.21376.
    1. Montano D. Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States. Front Public Health [Internet]. 2021;9:756633. Available from: .
    1. Jeet Kaur R, Dutta S, Charan J, Bhardwaj P, Tandon A, Yadav D, et al. Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database. Int J Gen Med [Internet]. 2021 Jul 27;14:3909–27. Available from: .
    1. Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS) Standard Operating Procedures for COVID-19 (as of 29 January 2021) [Internet]. 2021 Jan [cited 2022 Mar 30]. Available from: .
    1. Centers for Disease Control and Prevention. Vaccine safety publications [Internet]. 2022 [cited 2022 Mar 31]. Available from: .
    1. Patone M., Handunnetthi L., Saatci D., Pan J., Katikireddi S.V., Razvi S., et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021;27(12):2144–2153. doi: 10.1038/s41591-021-01556-7.
    1. Jabagi M.J., Botton J., Bertrand M., Weill A., Farrington P., Zureik M., et al. Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. JAMA. 2022;327(1):80–82. doi: 10.1001/jama.2021.21699.
    1. Barda N., Dagan N., Ben-Shlomo Y., Kepten E., Waxman J., Ohana R., et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021;385(12):1078–1090. doi: 10.1056/NEJMoa2110475.
    1. Mörl F, Günther M, Rockenfeller R. Is the Harm-to-Benefit Ratio a Key Criterion in Vaccine Approval? Frontiers in Medicine [Internet]. 2022;9. Available from: .
    1. Greenhalgh T, Fisman D, Cane DJ, Oliver M, Macintyre CR. Adapt or die: how the pandemic made the shift from EBM to EBM+ more urgent. BMJ Evid Based Med [Internet]. 2022 Jul 19;bmjebm – 2022–111952. Available from: .
    1. Hampton L.M., Aggarwal R., Evans S.J.W., Law B. General determination of causation between Covid-19 vaccines and possible adverse events. Vaccine. 2021;39(10):1478–1480. doi: 10.1016/j.vaccine.2021.01.057.
    1. Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ [Internet]. 2021 Jun 14 [cited 2022 Mar 28];373. Available from: .
    1. Lash TL, Fox MP, Fink AK. Applying Quantitative Bias Analysis to Epidemiologic Data [Internet]. Springer New York; 2009. 192 p. Available from: .
    1. MacLehose RF, Ahern TP, Lash TL, Poole C, Greenland S. The Importance of Making Assumptions in Bias Analysis. Epidemiology [Internet]. 2021 Sep 1;32(5):617–24. Available from: .
    1. Greenland S. Invited Commentary: Dealing With the Inevitable Deficiencies of Bias Analysis-and All Analyses. Am J Epidemiol. 2021 Aug 1;190(8):1617–21. Available from: 10.1093/aje/kwab069.
    1. Krumholz H.M., Ross J.S., Presler A.H., Egilman D.S. What have we learnt from Vioxx? BMJ. 2007;334(7585):120–123. doi: 10.1136/bmj.39024.487720.68.
    1. Nissen S.E., Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med. 2007;356(24):2457–2471. doi: 10.1056/NEJMoa072761.
    1. Anderson S. CBER Plans for Monitoring COVID-19 Vaccine Safety and Effectiveness [Internet]. VRBPAC Meeting; 2020 Oct 22 [cited 2022 Jul 19]. Available from: .
    1. Anderson S. An Update of FDA Monitoring COVID-19 Vaccine Safety and Effectiveness [Internet]. VRBPAC Meeting; 2021 Feb 26 [cited 2022 Jul 19]. Available from: .
    1. Anderson S. FDA Updates of COVID-19 Vaccine Safety Activities [Internet]. VRBPAC Meeting; 2021 Jun 10 [cited 2022 Jul 19]. Available from: .
    1. Food and Drug Administration. Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring [Internet]. 2021 Jan [cited 2021 Jul 19]. Available from: .
    1. Pfizer. 5.3.6 Cumulative analysis of post-authorization adverse event reports of PF-07302048 (BNT162b2) received through 28-Feb-2021 [Internet]. 2021 Apr [cited 2022 Jul 19]. Available from: .
    1. Gupta A., Madhavan M.V., Sehgal K., Nair N., Mahajan S., Sehrawat T.S., et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032. doi: 10.1038/s41591-020-0968-3.
    1. Lei Y., Zhang J., Schiavon C.R., He M., Chen L., Shen H., et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circ Res. 2021;128(9):1323–1326. doi: 10.1161/CIRCRESAHA.121.318902.
    1. Tanveer S, Rowhani-Farid A, Hong K, Jefferson T, Doshi P. Transparency of COVID-19 vaccine trials: decisions without data. BMJ Evid Based Med [Internet]. 2021 Aug 9; Available from: .
    1. Doshi P, Godlee F, Abbasi K. Covid-19 vaccines and treatments: we must have raw data, now. BMJ [Internet]. 2022 Jan 19;376:o102. Available from: .
    1. Benn CS, Schaltz-Buchholzer F, Nielsen S, Netea MG, Aaby P. Randomised Clinical Trials of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific Effects? [Internet]. 2022 [cited 2022 May 9]. Available from: .
    1. Murad M.H., Saadi S. Evidence-based medicine has already adapted and is very much alive. BMJ Evidence-based Medicine. 2022 doi: 10.1136/bmjebm-2022-112046.
    1. Munro A. The Pandemic Evidence Failure. 2022.
    1. Mansanguan S, Charunwatthana P, Piyaphanee W, Dechkhajorn W, Poolcharoen A, Mansanguan C. Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents. Trop. Med. Infect. Dis. 2022;7(8):196. doi: 10.3390/tropicalmed7080196.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi